A new drug could lead to 16% weight loss in patients and improve metabolic health, Phase III results show. 

Survodutide, a dual glucagon/GLP‑1 receptor agonist, has been developed by pharmaceutical company Boehringer Ingelheim for the treatment of adults living with obesity or overweight, without type 2 diabetes. 

The Phase III SYNCHRONIZE-1 trial showed patients lost an average of 16.6% weight after 76 weeks, using the efficacy estimand. Results also demonstrated up to 85.1% of adults achieved body weight reduction. 

Survodutide works by causing the loss of fat tissue, with results suggesting the drug has the potential to address obesity while also supporting liver function, a key regulator of metabolic health. 

“Today’s SYNCHRONIZE-1 topline results strengthen our confidence in survodutide as a treatment candidate capable of addressing obesity and potentially offering targeted weight loss to help address connected conditions including liver disease,” said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma, Boehringer Ingelheim.  

“Survodutide has the potential to be the first global glucagon/GLP-1 dual agonist to help the more than one billion people living with obesity and metabolic dysfunction-associated steatohepatitis (MASH).”   

“There is an urgent need for new therapies that go beyond weight reduction alone to support meaningful improvements in metabolic health,” added Professor Carel le Roux, Professor at University College in Dublin, Ireland, and Global Coordinating Investigator of the trial. 

“Survodutide’s dual agonism is particularly exciting, as it offers a promising approach to addressing this significant unmet need in care.”